Abstract
The main problems that the patient with superficial transitional cell carcinoma (TCC) faces are the lifelong risk of tumor recurrence, and the risk of tumor progression and death secondary to cancer. Historically, cystectomy was the primary and only availible treatment option for patients who had recurrent bladder cancer or carcinoma in situ (CIS). However, the development of topical (intravesical) therapies for transitional cell carcinoma of the bladder has revolutionized the management of both superficial papillary tumors, and of flat carcinoma in situ. Due to the discovery of intravesical agents that have biologic activity against superficial TCC of the bladder (such as Bacillus Calmette-Guerrin (BCG) and Mitomycin), the mortality rate from bladder cancer has decreased despite a concurrent increase in the incidence of this malignancy.1
Chapter PDF
References
Nseyo UO, Lamm DL: Immunotherapy of Bladder Cancer. Seminars in Surgical Oncology 13:342–349, 1997.
Brosman SA: Bacillus Calmette-Guerin Immunotherapy. Urol Clin N.A. 19:557–564, 1992.
Lamm DL. Complications of Bacillus Calmette-Guerin Immunotherapy. Urol Clin N.A. 19:565–572, 1992.
Sargent ER, Williams RD: Immunotherapeutic Alternatives in Superficial Bladder Cancer. Urol Clin N.A. 19:581–589, 1992.
Zhang Y, Khoo HE, Esuvranthan K: Effects of Bacillus Calmette-Guerrin and Interferon alpha on Human Bladder Cancer in vitro. Int J Cancer 71: 851–57, 1997.
Borden EC, Groveman DS, Nasu T, Reznikoff C, and Bryan GT: Antiproliferative Activities of Interferons Against Human Bladder Carcinoma Cell Lines in vitro. J Urol 132:800–803, 1984.
Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 1996;46:5–27.
Herr HW, Schwalb DM, Zhang Z-F, Sogani PC, Fair WR, Whitmore WF, Jr, and Oettgen HF. Intravesical Bacillus Calmette-Guerin Therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial. J Clin Oncol., 13:1404–1408, 1995.
Heney NM: Natural History of Superficial Bladder Cancer.Urol Clin N.A. 19:429–433, 1992.
Sarosdy MF: Principles of Intravesical Chemotherapy and Immunotherapy. Urol Clin N.A. 19:509–519, 1992.
Utz DC, Hanash KA, Farrow GM: The Plight of the Patient with Carcinoma in situ of the Bladder. J Urol 103:160–4, 1970.
Herr HW, Laudone VP, Badalament RA: Bacillus Calmette-Guerin Therapy Alters the Progression of Superficial Cancer. J Clin Oncol 6:1450–55, 1988.
Franklin J, and Benson MC: New techniques in management and treatment of superficial bladder cancer. In Neal DE (ed.): Tumors in Urology. London, Springer-Verlag, pp 65–78, 1994.
Lamm DL: BCG in Perspective: Advances in the treatment of superficial bladder cancer. Eur Urol., 27(Suppl):2–8, 1995.
Berry DL, Blumenstein BA, Magyary DL: Local Toxicity Patterns Associated with Intravesical bacillus Calmette-Guerrin: A Southwest Oncology Group Study. Int J Urol 3:98–101, 1995.
Isaacs A, and Lindenmann J: Virus inference: I. The interferon. Proc R Soc Lond (Biol), 147: 258–267, 1957
Kurzrock R, Gutterman JU, and Talpaz M: Interferon-a,b,g: basic principles and preclinical studies. DeVita VT, Jr. et al. (Eds): Biologic Therapy of Cancer, p 247. Philadelphia, JB Linnincott Co., 1991.
Baron S, Tyring SK, Fleischmann R, Coppenhaver DH, Niesel DW, Kimpel GR, Stanton J, Hughes TK: The Interferons. Mechanism of Action and Clinical Applications. JAMA 266:1365–1381, 1991.
Kurzrock R, Gutterman JU, and Talpaz M: Interferon-a,b,g: basic principles and preclinical studies. DeVita VT, Jr. et al. (Eds): Biologic Therapy of Cancer, p 247. Philadelphia, JB Linnincott Co., 1991.
Hawkyard S, James K, Prescott S, Jackson AM, Ritchie AWS, Smyth JF, Chisolm GD: The Effects of Recombinant Human Interferon-Gamma on a Panel of Uman Bladder Cancer Cell Lines. J Urol 145:1078–81, 1991.
Molto L, Alvarez-Mon M, Carballido J, Manzano L, Guillen C, Prieto A, Olivier C, and Rodriguez-Zapata M: Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. Br J Cancer, 70: 1247, 1994.
Patard J, Muscatelli-Groux B, Saint F, Popov Z, Maille P, Abbou C, Chopin D, et al. Evaluation of local immune response after intravesical bacille Calmette-Guerin treatemnt for superficial bladder cancer. Br. J. Urol. 78:709–714, 1996.
Tzai TS, Lin SN: Interferon alpha can alter the Lytic Susceptibility of Murine Bladder Transitional Cell Carcinoma (MBT-2) by Their Original Poor Specific Cytotoxic Tumor Infiltrating Lymphocytes. J Urol 146: 523/7, 1992.
Jackson AM, Alexandrov AB, Prescott S, James K, Chisolm GD: Expression of Adhesion Molecules by Bladder Cancer Cells: Modulation by Interferon-Gamma and Tumor Necrosis Factor. J Urol 148:1583, 1992.
Alverez-Mon M, Molto LM, Manzano L, Olivier C, and Carballido JA: Immunomodulatory effect of inter-feron-a2b on natural killer cells and T lymphocytes from patients with transitional cell carcinoma of the bladder. Anti-Cancer Drugs, 3(Suppl): 5, 1992.
Molto L, Carballido J, Manzano L, Reyes E, Oliver C, Alvarez-Mon, M: Prophylactic Intracavitary Treatment with Interferon alpha Increases Interferon gamma production by Peripheral Blood Mononuclear Cells in Patients with Superficial Transitional Cell Carcinoma of the Bladder. Brit J Cancer 75:1849–53, 1997.
Fuchsberger N, Kubes M, Kontsek P, Borecky L, Hornak M, Godal A, Silvanova, Svec J: In vitro antiproliferative effect of interferon alpha in solid tumors: a potential predictive test. Neoplasma, 40: 293–6, 1993.
Boccardo F, Cannata D, Rubagotti A, Guarnen D, Decensi A, Canobbio L Curotto A, Martorana G, Pe-goraro C, Selvaggi F, Salvia G, Comeri G, Bano A, Borella T, and Giuliani L: Prophylaxis of superficial bladder cancer with mitomycin or interferon alpha-2b: Results of a multicentric Italian study. J Clin One, 12: 7, 1994.
Scorticatti C, de la Pena N, Bellora O, et al.: Systemic IFN-alpha treatment of multiple bladder papilloma grade I or II patients: pilot study. J Interferon Res., 2: 339–43, 1987.
Ikic D, Nola P, Maricic Z, et al.: Application of human leukocyte interferon in patients with urinary bladder papillomatosis, breast cancer, and melanoma. Lancet 1: 1022, 1981.
Di Stasi SM, Virgili G, Vespasiani G, Porena M, and Micali F: Intralesional alpha interferon therapy in papillary superficial transitional cell carcinoma of the bladder: A pilot study. B J Urol., 71: 422, 1993.
Koenig F, McGovern FJ: Fluorescence Detection of Bladder Carcinoma. Urology 50:778–9, 1997.
Ikic D, Nola P, Maricic Z, et al.: Application of human leukocyte interferon in patients with urinary bladder papillomatosis, breast cancer, and melanoma. Lancet 1: 1022, 1981.
Oliver R, Waxman J, Kwok H, et al.: Alpha lymphoblastoid interferon for non-invasive bladder cancer. Br J Cancer 53:432, 1986.
Torti FM, Shortliffe LD, Williams RD, Pitts WC, Kempson RL, Ross JC, Palmer J, Meyers F, Farrari M, Hannigan J, Spiegel R, McWhirter K, and Freiha F: Alpha-interferon in superficial bladder cancer: A Northern California Oncology Group Study. J Clin One, 6: 476, 1988.
Glashan RW: A randomized controlled study of intravesical a-2b-interferon in carcinoma in situ of the bladder. J Urol., 144: 658, 1990.
Niijima T: Intravesical treatment of bladder cancer with recombinant human interferon-b. Cancer Immunol Immunoth., 30: 81, 1989.
Geboers ADH, Van Bergen TNLM, and Ousterlinck W: Gamma-interferon in the therapeutic and prophylactic management of superficial bladder cancer: J Urol 137:276A, abstract 691, 1987.
Geboers ADH, Van Bergen TNLM, and Ousterlinck W: Gamma-interferon in the therapeutic and prophylactic management of superficial bladder cancer: J Urol 137:276A, abstract 691, 1987.
Migliari R, El Demiry M, Muscas G, and Usai E: Intravesical instillation of beta-interferon in the treatment of bladder cancer. Brit J Urol., 70: 169, 1992.
Kostakopoulos A, Deliveliotis Ch, Mavromanolakis E, Aravnatinos G, and Dimopoulos MA: Intravesical interferon alpha-2b administration in the treatment of superficial bladder cancer. Eur Urol., 18: 201, 1990.
Bartoletti R, Massimini G, Criscuolo D, and Rizzo M: Interferon alpha 2a in superficial bladder cancer prophylaxis: Toleration and long-term follow-up. A phase I-II study. Anti-Cancer Res., 11: 2167, 1991.
Boccardo F, Cannata D, Rubagotti A, Guameri D, Decensi A, Canobbio L Curotto A, Martorana G, Pe-goraro C, Selvaggi F, Salvia G, Comeri G, Bano A, Borella T, and Giuliani L: Prophylaxis of superficial bladder cancer with mitomycin or interferon alpha-2b: Results of a multicentric Italian study. J Clin One, 12: 7, 1994.
Boccardo F, Cannata D, Rubagotti A, Guameri D, Decensi A, Canobbio L Curotto A, Martorana G, Pe-goraro C, Selvaggi F, Salvia G, Comeri G, Bano A, Borella T, and Giuliani L: Prophylaxis of superficial bladder cancer with mitomycin or interferon alpha-2b: Results of a multicentric Italian study. J Clin One, 12: 7, 1994.
Hoetl W, Hasun R, Albrecht W, Marberger M: How effective is topical alpha-2b interferon in preventing recurrence of superficial bladder cancer? Brit J Urol., 68: 495, 1991.
Okamoto E, Kinne RKH, Sokeland J: Interferons modify in vitro proliferation of human bladder transitional cell carcinoma in the presence of doxorubicin and mitomycin C: J Urol 156:1492–95, 1996.
Kalbe T, Beer M, Mendoza E, Ikinger U, Link M, Reichert HE, Frangenheim T, Klein E, and Fabricius PG: BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study. Urologe Ausgabe a, 33: 133–7, 1994.
Donovan MG, Grainger R, Hegarty JH, et al.: A prospective, randomized study of intravesical BCG and interferon in superficial bladder cancer. Presented as a poster at the 4th European Conf on Clinical Oncology and Cancer Nursing, Madrid 1987.
Jiminez-Cruz JF, Vera-Donoso CD, Leiva O, Pamplona M, Rioja-Sanz LA, Martinez-Lasierra MM, Flores N, Unda M: Intravesical Immunoprophylaxis in Recurrent Superficial Bladder Cancer (Stage T1): Multicenter Trial Comparing BCG and Interferon-Alpha. Urology 50:529–535, 1997.
Portillo J, Martin J, Hernandez R, Correas M, Gutierrez J, Valle JD, Roca A, Vega A, Villanueva A, Gutierrez R: Results at 43 Months’ Follow-up of a Double Blind, Randomized, Prospective Clinical Trial Using Intravesical Interferon Alpha 2b in the Prophylaxis of Stage pT1 Trasitional Cell Carcinoma of the Bladder. Urology 49:187–190, 1997.
Lamm DL: Results at 43 Months’ Follow-up of a Double Blind, Randomized, Prospective Clinical Trial Using Intravesical Interferon Alpha 2b in the Prophylaxis of Stage pT1 Trasitional Cell Carcinoma of the Bladder (Editorial). Urology 49:190, 1997.
Engelmann U, Knopf H, Graff J, and the Project Group Bochum-interferon and superficial bladder cancer: Interferon-a2b instillation prophylaxis in superficial bladder cancer—a prospective, controlled three-arm trial. Anti-Cancer Drugs, 3: 33, 1992.
Ferrari P, Castagnetti G, Pollastri CA, Ferrari G, Tavoni F, Grassi D: Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: Interferon-a2b with epirubicin. Anti-Cancer Drugs, 3: 25, 1992.
Gomella LG, Keeley FX, Jr., McCue PA, and Lattime EC: A comparison of the local immune response to intravesical alpha-interferon and Bacillus Calmette-Guerin (BCG) in patients with superficial bladder cancer. J Urol., 151: 473A, 1994.
Downs T, Szilvasi, O’Donnel M: Pharmacological Biocompatibility between intravesical preparations of BCG and Interferon-Alfa 2B. J Urol 158:2311–2315, 1997.
Pagano F, Bassi P, Miiani C, Meneghini A, Maruzzi D, Garbeglio A: A Low Dose Bacillus Calmette-Guer-rin Regimen in Superficial Bladder Cancer Therapy: Is It Effective? J Urol 146:32–35, 1991.
Strieker P, Pryor K, Nicholson T, Goldstein D, Golovsky D, Ferguson R, Nash P, Ehsman S, Rumma J, Mammen G, Penny R Bacillus Calmette-Guerin plus intravesical interferon alpha-2β in patients with superficial bladder cancer. Urology 48:957–961, 1996.
O’Donnell MA, Chen X, Luo Y, DeWolf WC: Experimental and Clinical Evidence of Enhancement of BCG Efficacy by Adding Interferon-Alpha. J Urol 157:1502A, 1997.
O’Donnell MA: Personal Communication, 1998.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Naitoh, J., Franklin, J., O’Donnell, M.A., Belldegrun, A.S. (1999). Interferon Alpha for the Treatment of Superficial Bladder Cancer. In: Baskin, L.S., Hayward, S.W. (eds) Advances in Bladder Research. Advances in Experimental Medicine and Biology, vol 462. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4737-2_29
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4737-2_29
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7147-2
Online ISBN: 978-1-4615-4737-2
eBook Packages: Springer Book Archive